發(fā)布時間：2018-04-26 15:20

  本文選題：丙種球蛋白注射劑 + 阿司匹林腸溶片��； 參考：《中國臨床藥理學雜志》2017年15期

【摘要】：目的觀察丙種球蛋白注射劑聯(lián)合阿司匹林腸溶片治療川崎病的臨床療效及安全性。方法將88例川崎病患兒隨機分為對照組44例和試驗組44例。對照組予以阿司匹林50 mg·d~(-1),tid,口服;試驗組在對照組治療的基礎上,予以人血丙種球蛋白1.5 m L,一次性肌內注射。2組患兒均治療14 d。比較2組患兒的臨床療效、白細胞介素~(-1)7(IL~(-1)7)、IL-6、血管內皮生長因子(VEGF)、基質金屬蛋白酶-2(MMP-2)、MMP-9水平、內皮細胞數量,以及藥物不良反應的發(fā)生情況。結果治療后,試驗組和對照組的總有效率分別為90.91%(40/44例)和77.27%(34/44例),差異有統(tǒng)計學意義(P0.05)。治療后,試驗組與對照組的IL~(-1)7分別為(17.32±3.83)和(42.67±4.38)ng·L~(-1),IL-6分別為(24.19±5.32)和(56.47±6.29)ng·L~(-1),VEGF分別為(109.73±18.17)和(147.32±17.69)ng·L~(-1),MMP-2分別為(0.47±0.15)和(0.84±0.17)ng·m L~(-1),MMP-9分別為(0.43±0.11)和(0.93±0.23)ng·m L~(-1),內皮細胞數量分別為(2.56±0.74)和(1.58±0.15)cell·μL~(-1),差異均有統(tǒng)計學意義(均P0.05)。試驗組發(fā)生的藥物不良反應主要有冠狀動脈病變和膽囊積液,對照組發(fā)生的藥物不良反應主要有冠狀動脈病變、關節(jié)炎、膽囊積液,且試驗組和對照組的藥物不良反應發(fā)生率分別為6.82%和31.82%,差異有統(tǒng)計學意義(P0.05)。結論丙種球蛋白注射劑聯(lián)合阿司匹林腸溶片治療川崎病的臨床療效顯著,且安全性較高。
[Abstract]:Objective to observe the efficacy and safety of gamma globulin injection combined with aspirin enteric-coated tablets in the treatment of Kawasaki disease. Methods 88 children with Kawasaki disease were randomly divided into control group (n = 44) and experimental group (n = 44). The control group was given aspirin 50 mg / d for oral administration, and the experimental group was given human gamma globulin 1.5 mL on the basis of treatment in the control group, and all the children in the control group were treated with intramuscular injection of 2.0 mg / L for 14 days. The clinical efficacy of the two groups was compared. The levels of IL-6, VEGF, MMP-2, MMP-9, the number of endothelial cells and the occurrence of adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 90.91% 40 / 44 cases and 77.27% / 44 cases respectively. The difference was statistically significant (P 0.05). 娌葷枟鍚，

本文編號：1806572